WO2000052198A1 - Methods for identifying compounds useful for inhibiting farnesyl diphosphate synthase - Google Patents
Methods for identifying compounds useful for inhibiting farnesyl diphosphate synthase Download PDFInfo
- Publication number
- WO2000052198A1 WO2000052198A1 PCT/US2000/005338 US0005338W WO0052198A1 WO 2000052198 A1 WO2000052198 A1 WO 2000052198A1 US 0005338 W US0005338 W US 0005338W WO 0052198 A1 WO0052198 A1 WO 0052198A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mammal
- diphosphate synthase
- nanom
- farnesyl diphosphate
- bone
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
Definitions
- the present invention relates to methods for identifying compounds useful as inhibitors of farnesyl diphosphate synthase. More particularly, the compounds so identified are useful for inhibiting bone resorption.
- the present invention also relates to methods for inhibiting bone reso ⁇ tion in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of a farnesyl diphosphate synthase inhibitor.
- disorders in humans and other mammals involve or are associated with abnormal bone resorption.
- Such disorders include, but are not limited to, osteoporosis, glucocorticoid induced osteoporosis, Paget's disease, abnormally increased bone turnover, periodontal disease, tooth loss, bone fractures, rheumatoid arthritis, periprosthetic osteolysis, osteogenesis imperfecta, metastatic bone disease, hypercalcemia of malignancy, and multiple myeloma.
- osteoporosis which in its most frequent manifestation occurs in postmenopausal women.
- Osteoporosis is a systemic skeletal disease characterized by a low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture. Osteoporotic fractures are a major cause of morbidity and mortality in the elderly population. As many as 50% of women and a third of men will experience an osteoporotic fracture. A large segment of the older population already has low bone density and a high risk of fractures. There is a significant need to both prevent and treat osteoporosis and other conditions associated with bone resorption. Because osteoporosis, as well as other disorders associated with bone loss, are generally chronic conditions, it is believed that appropriate therapy will typically require chronic treatment.
- Normal bone physiology involves a process wherein bone tissue is continuously being turned over by the processes of modeling and remodeling. In other words, there is normally an appropriate balance between reso ⁇ tion of existing bone tissue and the formation of new bone tissue. The exact mechanism underlying the coupling between bone reso ⁇ tion and formation is still unknown. However, an imbalance in these processes is manifested in various disease states and conditions of the skeleton.
- osteoblasts Two different types of cells called osteoblasts and osteoclasts are involved in the bone formation and reso ⁇ tion processes, respectively. See H. Fleisch, Bisphosphonates In Bone Disease, From The Laboratory To The Patient, 3rd Edition, Parthenon Publishing (1997), which is inco ⁇ orated by reference herein in its entirety.
- Osteoblasts are cells that are located on the bone surface. These cells secrete an osseous organic matrix, which then calcifies. Substances such as fluoride, parathyroid hormone, and certain cytokines such as protaglandins are known to provide a stimulatory effect on osetoblast cells. However, an aim of current research is to develop therapeutic agents that will selectively increase or stimulate the bone formation activity of the osteoblasts.
- Osteoclasts are usually large multinucleated cells that are situated either on the surface of the cortical or trabecular bone or within the cortical bone. The osteoclasts resorb bone in a closed, sealed-off microenvironment located between the cell and the bone. The recruitment and activity of osteoclasts is known to be influenced by a series of cytokines and hormones. It is well known that bisphosphonates are selective inhibitors of osteoclastic bone reso ⁇ tion, making these compounds important therapeutic agents in the treatment or prevention of a variety of systemic or localized bone disorders caused by or associated with abnormal bone reso ⁇ tion. However, despite the utility of bisphosphonates, there remains the desire amongst researchers to develop additional therapeutic agents for inhibiting the bone reso ⁇ tion activity of osteoclasts.
- the mevalonate biosynthetic pathway is an important pathway of osteoclast function. This pathway is involved in the bisosynthesis of cholesterol and of isoprenoids, some of which are used in protein prenylation.
- the enzyme farnesyl disphosphate synthase (FPP synthase) mediates the synthesis of farnesyl diphosphate by catalyzing the sequential condensation of two molecules of isopentenyl diphosphate (LPP) with one molecule of dimethylallyl diphosphate (DMAPP) to produce geranyl diphosphate (GPP) and then farnesyl diphosphate (FPP).
- Farnesyl diphosphate is essential for the farnesylation of several proteins required for cytoskeletal organization and vesicular traffic. Interference with the function of these proteins can also lead to apoptosis, i.e. programmed cell death. Therefore, farnesyl diphosphate synthase, the enzyme involved in the synthesis of farnesyl diphosphate, is essential for the proper biological functioning of the osteoclasts.
- nitrogen- containining bisphosphonates such as alendronate and risedronate are specific nanomolar inhibitors of farnesyl diphosphate synthase. It is also su ⁇ risingly found that it is possible to identify other compounds useful as farnesyl disphosphate synthase inhibitors.
- inhibitors of farnesyl diphosphate synthase are useful for inhibiting bone reso ⁇ tion. Without being limited by theory, it is believed that these inhibitors are responsible for inhibiting the bone reso ⁇ tion activity of the osteoclasts.
- It is an object of the present invention to provide methods for inhibiting farnesyl diphosphate synthase in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of a farnesyl disphosphate synthase inhibitor having an IC50 value from about 0.01 nanoM to about 1000 nanoM.
- It is another object of the present invention to provide methods for treating or reducing the risk of contracting a disease state or condition involving or affecting bone tissue in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of a farnesyl disphosphate synthase inhibitor having an IC50 value from about 0.01 nanoM to about 1000 nanoM.
- It is an object of the present invention to provide methods for inhibiting farnesyl diphosphate synthase activity in a mammal comprising administering to a mammal in need thereof comprising administering to a mammal in need thereof a therapeutically effective amount of the combination of: (a) a farnesyl disphosphate synthase inhibitor having an IC50 value from about 0.01 nanoM to about 1000 nanoM, and (b) a bisphosphonate active.
- It is an object of the present invention to provide methods for treating or reducing the risk of contracting a disease state or condition involving or affecting bone tissue in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of the combination of: (a) a farnesyl disphosphate synthase inhibitor having an IC50 value from about 0.01 nanoM to about 1000 nanoM, and (b) a bisphosphonate active.
- the present invention relates to methods for identifying compounds useful as farnesyl diphosphate synthase inhibitors, comprising: a). contacting a putative farnesyl diphosphate synthase inhibitor with a farnesyl diphosphate synthase solution, and b). determining the farnesyl diphosphate synthase activity of said solution with a farnesyl diphosphate synthase solution not contacted with said putative inhibitor.
- the present invention also relates to methods for inhibiting farnesyl diphosphate synthase in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of a farnesyl disphosphate synthase inhibitor having an IC50 value from about 0.01 nanoM to about 1000 nanoM.
- the present invention also relates to methods for inhibiting bone reso ⁇ tion in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of a farnesyl disphosphate synthase inhibitor having an IC50 value from about 0.01 nanoM to about 1000 nanoM.
- the present invention also relates to methods for treating or reducing the risk of contracting a disease state or condition mediated by farnesyl disphosphate synthase in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of a farnesyl disphosphate synthase inhibitor having an IC50 value from about 0.01 nanoM to about 1000 nanoM.
- the present invention also relates to methods for treating or reducing the risk of contracting a disease state or condition involving or affecting bone tissue in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of a farnesyl disphosphate synthase inhibitor having an IC50 value from about 0.01 nanoM to about 1000 nanoM.
- the present invention also relates to methods for inhibiting farnesyl diphosphate synthase activity in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of the combination of: (a) a farnesyl disphosphate synthase inhibitor having an IC50 value from about 0.01 nanoM to about 1000 nanoM, and (b) a bisphosphonate active.
- the present invention also relates to methods for inhibiting bone reso ⁇ tion in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of the combination of: (a) a farnesyl disphosphate synthase inhibitor having an IC50 value from about 0.01 nanoM to about 1000 nanoM, and (b) a bisphosphonate active.
- the present invention also relates to methods for treating or reducing the risk of contracting a disease state or condition mediated by farnesyl diphosphate synthase comprising administering to a mammal in need thereof a therapeutically effective amount of the combination of: (a) a farnesyl disphosphate synthase inhibitor having an IC50 value from about 0.01 nanoM to about 1000 nanoM, and (b) a bisphosphonate active.
- the present invention also relates to methods for treating or reducing the risk of contracting a disease state or condition involving or affecting bone tissue in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of the combination of: (a) a farnesyl disphosphate synthase inhibitor having an IC50 value from about 0.01 nanoM to about 1000 nanoM, and (b) a bisphosphonate active.
- the present invention also relates to pharmaceutical compositions comprising a therapeutically effective amount of a farnesyl disphosphate synthase inhibitor having an IC50 value from about 0.01 nanoM to about 1000 nanoM.
- the present invention also relates to pharmaceutical compositions comprising a therapeutically effective amount of the combination of: (a) a farnesyl disphosphate synthase inhibitor having an IC50 value from about 0.01 nanoM to about 1000 nanoM and (b) a bisphosphonate active.
- the present invention also relates to the use of such compositions in the manufacture of a medicament for the methods disclosed herein.
- the present invention relates to methods for identifying compounds useful as farnesyl diphosphate synthase inhibitors and for inhibiting this enzyme with the compounds so identifited.
- the mevalonate biosynthetic pathway is an important pathway of osteoclast function. This pathway is involved in the bisosynthesis of cholesterol and of isoprenoids, some of which are used in protein prenylation. It would be highly desirable to identify and develop compounds useful as selective inhibitors of farnesyl diphosphate synthase in the osteoclasts. Such inhibitors would be useful for inhibiting ostetoclast function, thereby inhibiting undesired bone reso ⁇ tion and its manifestations in various disease states and conditions.
- Farnesyl diphosphate synthase is also known by the following names: prenyltransferase, dimethylallyltransferase, and dimethylallyl diphosphate:isopentenyl diphosphate dimethylallyltransferase.
- Alendronate (4-amino-l-hydroxybutylidene- 1,1 -bisphosphonate) is a potent inhibitor of bone reso ⁇ tion, used in the treatment and prevention of osteoporosis and other bone diseases. Without being limited by theory, it is believed that alendronate and other bisphosphonates are readily adsorbed onto the bone surface and are selectively taken up by osteoclasts during bone reso ⁇ tion. It is generally accepted that at the cellular level bisphosphonates act by inhibiting osteoclast activity. The effects of alendronate monosodium trihydrate and of the HMG-CoA reductase inhibitor, lovastatin, on osteoclasts in culture is known.
- Osteoclast formation and bone reso ⁇ tion are inhibited by alendronate monosodium trihydrate and by lovastatin.
- Mevalonic acid lactone or geranylgeraniol reverse the effects of lovastatin but only geranylgeraniol reverses the effects of alendronate, thereby supporting the hypothesis that alendronate monosodium trihydrate induces apoptosis by inhibiting protein prenylation via inhibition of the mevalonate pathway prior to the formation of geranylgeranyl diphosphate.
- ntirogen-containing bisphosphonates are potent inhibitors of any of several enzymes involved in isoprenoid synthesis.
- geranylgeranyl diphosphate from mevalonate involves six enzymes, mevalonate (MVA) kinase (EC 2.7.1.36), phosphomevalonate (MVAP) kinase (EC 2.7.4.2), mevalonate diphosphate (MVAPP) decarboxylase, isopentenyl diphosphate (IPP) isomerase (EC 5.3.3.2), farnesyl diphosphate (FPP) synthase (EC 2.5.1.1), and geranylgeranyl diphosphate (GGPP) synthase.
- MVA mevalonate
- MVAP phosphomevalonate
- MVAPP mevalonate diphosphate
- IPP isopentenyl diphosphate
- FPP farnesyl diphosphate
- GGPP geranylgeranyl diphosphate
- Farnesyl protein transferase geranylgeranyl protein transferase I
- geranylgeranyl protein transferase II geranylgeranyl protein transferase II
- FTase Farnesyl protein transferase
- GCTase I geranylgeranyl protein transferase I
- GGTase LI geranylgeranyl protein transferase II
- nitrogen-containing bisphosphonates such as alendronate monosodium trihydrate are specific and potent inhibitors of farnesyl diphosphate synthase. This specificity is seen in that high micromolar concentrations of alendronate monosodium trihydrate do not inhibit any other enzyme in the mevalonate pathway.
- alendronate inhibition of osteoclast activity in vitro is prevented by geranylgeraniol, consistent with alendronate inhibition of the mevalonate pathway, resulting in a decrease in cellular GGPP.
- the su ⁇ rising findings in the present invention show that alendronate, which is a nitrogen-containing bisphosphonate, is a specific inhibitor of FPP synthase and that it does not inhibit any other enzymes involved in the conversion of MVA to GGPP.
- the present invention also su ⁇ risingly demonstrates that alendronate and other nitrogen-containing bisphosphonates inhibit farnesyl diphosphate synthase and lower the concentration of the isoprenylation substrate farnesyl diphosphate and the downstream product geranylgeranyl diphosphate.
- lipids are essential for the prenylation of several proteins including GTP binding proteins of around 20 KDa, including those belonging to the rho, rac, CdC42 and rab families. These proteins are essential for cytoskeletal organization and vesicular traffic. Inactivation of rhoA, for example, causes osteoclast inactivation, and rab is implicated in vesicular fusion to membranes, which is impaired following alendronate administration. Interference with the function of these proteins also leads to apoptosis.
- the IC50 for alendronate inhibition of farnesyl disphosphate synthase is 340 nanoM and for pamidronate inhibition of farnesyl disphosphate synthase is 500 nanoM.
- nitrogen-containing bisphosphonates have a different mechanism of action from non-nitrogen-containing bisphosphonates.
- Three nitrogen-containing bisphosphonates, alendronate, risedronate, and pamidronate effectively inhibit farnesyl diphosphate synthase, wherease the two non-nitrogen-containing bisphosphonate, etidronate and clodronate, have little or no effect on farnesyl diphosphate synthase.
- the present invention relates to a method for identifying an inhibitor of farnesyl diphosphate synthase comprising: a). contacting a putative farnesyl diphosphate synthase inhibitor with a farnesyl diphosphate synthase assay solution, and b). determining, i.e. comparing, the farnesyl diphosphate synthase activity of said assay solution with a farnesyl diphosphate synthase assay solution not contacted with said putative inhibitor, in order to determine the amount of inhibition.
- the farnesyl diphosphatesynthase assay solution is typically an aqueous solution.
- the inhibition effect is measured with respect to the catalysis of an appropriate reaction that one of ordinary skill in the art can select.
- Typical substrates include dimethylallyl diphosphate, isopentenyl diphosphate, and geranyl diphosphate. Reaction times, conditions, quatitation methods, and other variables are chosen for convenience to obtain a readily quantitated system for measuring the inhibition of the farnesyl diphosphate synthase.
- the enzyme can be used in a crude, unpurified state, from various tissues sources, e.g., liver. Alternatively, the enzyme can be used in a partially purified state, a purified state, or as an expressed form of the enzyme, e.g., the expressed human enzyme.
- the present invention relates to methods for inhibiting bone reso ⁇ tion in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of a farnesyl diphosphate synthase inhibitor.
- the methods and compositions of the present invention are useful for both treating and reducing the risk of contracting disease states or conditions involving or associated with abnormal bone reso ⁇ tion.
- Such disease states or conditions include, but are not limited to, osteoporosis, glucocorticoid induced osteoporosis, Paget's disease, abnormally increased bone turnover, periodontal disease, tooth loss, bone fractures, rheumatoid arthritis, periprosthetic osteolysis, osteogenesis imperfecta, metastatic bone disease, hypercalcemia of malignancy, and multiple myeloma.
- the methods and compositions are also useful for both teating and reducing the risk of contracting other disease states or conditions mediated by farnesyl disphosphate synthase.
- the methods comprise administering a therapeutically effective amount of the combination of (a) a farnesyl diphosphate synthase inhibitor, which can itself be a bisphosphonate active, and (b) an additional bisphosphonate active.
- a farnesyl diphosphate synthase inhibitor which can itself be a bisphosphonate active
- an additional bisphosphonate active Both concurrent and sequential administration of the farnesyl disphosphate synthase inhibitor and the additional bisphosphonate active are deemed within the scope of the present invention.
- the farnesyl diphosphate synthase inhibitor and the additional bisphosphonate can be administered in either order.
- the farnesyl diphosphate synthase inhibitor and the additional bisphosphonate are typically administered within the same 24 hour period.
- the farnesyl diphosphate synthase inhibitor and the additional bisphosphonate are typically administered within about 4 hours of each other.
- therapeutically effective amount means that amount of the farnesyl diphosphate synthase inhibitor, or other actives of the present invention, that will elicit the desired therapeutic effect or response or provide the desired benefit when administered in accordance with the desired treatment regimen.
- a prefered therapeutically effective amount is a bone reso ⁇ tion inhibiting amount.
- “Pharmaceutically acceptable” as used herein means generally suitable for administration to a mammal, including humans, from a toxicity or safety standpoint.
- the farnesyl diphosphate synthase inhibitor is typically administered for a sufficient period of time until the desired therapeutic effect is achieved.
- the term "until the desired therapeutic effect is achieved”, as used herein, means that the therapeutic agent or agents are continuously administered, according to the dosing schedule chosen, up to the time that the clinical or medical effect sought for the disease or condition being mediated is observed by the clinician or researcher.
- the compounds are continuously administered until the desired change in bone mass or structure is observed. In such instances, achieving an increase in bone mass or a replacement of abnormal bone structure with normal bone structure are the desired objectives.
- the compounds are continuously administered for as long as necessary to prevent the undesired condition. In such instances, maintenance of bone mass density is often the objective.
- Nonlimiting examples of administration periods can range from about 2 weeks to the remaining lifespan of the mammal.
- administration periods can range from about 2 weeks to the remaining lifespan of the human, preferably from about 2 weeks to about 20 years, more preferably from about 1 month to about 20 years, more preferably from about 6 months to about 10 years, and most preferably from about 1 year to about 10 years.
- compositions of the present invention comprise a therapeutically effective amount of a farnesyl diphosphate synthase inhibitor.
- compositions can further comprise a pharmaceutically- acceptable carrier.
- compositions can also comprise an additional active.
- Farnesyl Diphosphate Synthase Inhibitor The methods and compositions of the present invention comprise a farnesyl diphosphate synthase inhibitor. These inhibitors can in themselves be bisphosphonates.
- the farensyl diphosphate synthase inhibitors useful herein generally have an IC50 value from about 0.01 nM to about 1000 nanoM, although inhibitors with activities outside this range can be useful depending upon the dosage and route of administration.
- the inhibitors have an IC50 value of from about 0.01 nM to about 100 nM.
- the inhibitors have an IC5 Q value of from about 0.01 nM to about 1 nM.
- IC50 is a common measure of inhibition activity well known to those of ordinary skill in the art and is defined as the concentration of the inhibitor needed to obtain a 50% reduction in the activity of the farnesyl disphosphate synthase.
- the precise dosage of the farnesyl diphosphate synthase inhibitor will vary with the dosing schedule, the particular compound chosen, the age, size, sex and condition of the mammal or human, the nature and severity of the disorder to be treated, and other relevant medical and physical factors. Thus, a precise pharmaceutically effective amount cannot be specified in advance and can be readily determined by the caregiver or clinician. Appropriate amounts can be determined by routine experimentation from animal models and human clinical studies. Generally, an appropriate amount is chosen to obtain an inhibition of the farnesyl diphosphate synthase activity so as to obtain a bone reso ⁇ tion inhibiting effect.
- an effective oral dose of the farnesyl diphosphate synthase inhibitor is about 1 ⁇ g/kg to about 1000 ⁇ g/kg, preferably about 10 ⁇ g/kg, for a human subject.
- human doses which can be administered are generally in the range of about 0.1 mg/day to about 10 mg/day, preferably from about 0.25 mg/day to about 5 mg/day, and more preferably from about 0.5 mg/day to about 1.5 mg/day, based on a geranylgeraniol active weight basis.
- a typical nonlimiting dosage amount would be about 0.75 mg/day.
- the pharmaceutical compositions herein comprise from about 0.1 mg to about 10 mg, preferably from about 0.25 mg to about 5 mg, and more preferably from about 0.5 mg to about 1.5 mg of the farnesyl diphosphate synthase inhibitor.
- a typical nonlimiting amount is about 0.75 mg.
- the methods and compositions of the present invention can further comprise a bisphosphonate active or a pharmaceutically acceptable salt thereof.
- bisphosphonate actives are defined herein to be distinct from and not to included the farnesyl diphosphate synthase inhibitors of the present invention, because certain nitrogen-containing bisphosphonates, e.g., alendronate are found to have activity as farnesyl diphosphate synthase inhibitors.
- the present invention can include the combination of a farnesyl diphosphate synthase inhibitor which happens to have a bisphosphonate structure and an additional bisphosphonate active which does not necessarily have activity as a farnesyl diphosphate synthase inhibitor.
- nitrogen-containing means that the bisphosphonate compound or pharmaceutically acceptable salt thereof comprises at least one nitrogen atom in the bisphosphonate portion of the molecule.
- any nitrogen atom contained in the positive counter ion of such a salt e.g., the nitrogen atom of an ammonium counter ion, would not be considered in meeting the "nitrogen-containing" definition.
- alendronic acid i.e. 4-amino-l-hydroxybutylidene-l,l- bisphosphonic acid is an example of a nitrogen-containing bisphosphonate.
- the ammonium salt of the unsubstituted 1-hydroxybutylidene- 1,1 -bisphosphonic acid would not be a nitrogen-containing bisphosphonate as defined herein.
- n is an integer from 0 to 7 and wherein A and X are independently selected from the group consisting of H, OH, halogen, NH2, SH, phenyl, C1-C30 alkyl, C3- C30 branched or cycloalkyl, C1-C30 substituted alkyl, C1-C10 alkyl substituted NH2, C3-C10 branched or cycloalkyl substituted NH2, C1-C10 dialkyl substituted NH2, C3-C10 branched or cycloalkyl disubstituted NH2, C1-C10 alkoxy, C1-C10 alkyl substituted thio, thiophenyl, halophenylthio, C1-C10 alkyl substituted phenyl, pyridyl, furanyl, pyrrolidinyl, imidazolyl, imidazopyridinyl, and benzyl, such that both A and X are independently
- the alkyl groups can be straight, branched, or cyclic, provided that sufficient atoms are selected for the chemical formula.
- the C1-C30 substituted alkyl can include a wide variety of substituents, nonlimiting examples which include those selected from the group consisting of phenyl, pyridyl, furanyl, pyrrolidinyl, imidazonyl, NH2, C1-C10 alkyl or dialkyl substituted NH2, OH, SH, and Cl -CIO alkoxy.
- the foregoing chemical formula is also intended to encompass complex carbocyclic, aromatic and hetero atom structures for the A and/or X substituents, nonlimiting examples of which include naphthyl, quinolyl, isoquinolyl, adamantyl, and chlorophenylthio.
- a non-limiting class of structures useful in the instant invention are those in which A is selected from the group consisting of H, OH, and halogen, X is selected from the group consisting of C1-C30 alkyl, C1-C30 substituted alkyl, halogen, and C1-C10 alkyl or phenyl substituted thio, and n is 0.
- a non-limiting subclass of structures useful in the instant invention are those in which A is selected from the group consisting of H, OH, and Cl, X is selected from the group consisting of C1-C30 alkyl, C1-C30 substituted alkyl, Cl, and chlorophenylthio, and n is 0.
- a non-limiting example of the subclass of structures useful in the instant invention is when A is OH and X is a 3-aminopropyl moiety, and n is 0, so that the resulting compound is a 4-amino-l,-hydroxybutylidene- 1,1 -bisphosphonate, i.e. alendronate.
- Pharmaceutically acceptable salts and derivatives of the bisphosphonates are also useful herein.
- Nonlimiting examples of salts include those selected from the group consisting alkali metal, alkaline metal, ammonium, and mono-, di, tri-, or tetra-Cl-C30-alkyl-substituted ammonium.
- Preferred salts are those selected from the group consisting of sodium, potassium, calcium, magnesium, and ammonium salts.
- Nonlimiting examples of derivatives include those selected from the group consisting of esters, hydrates, and amides.
- bisphosphonate and “bisphosphonates”, as used herein in referring to the therapeutic agents of the present invention are meant to also encompass diphosphonates, biphosphonic acids, and diphosphonic acids, as well as salts and derivatives of these materials.
- the use of a specific nomenclature in referring to the bisphosphonate or bisphosphonates is not meant to limit the scope of the present invention, unless specifically indicated. Because of the mixed nomenclature currently in use by those or ordinary skill in the art, reference to a specific weight or percentage of a bisphosphonate compound in the present invention is on an acid active weight basis, unless indicated otherwise herein.
- the phrase "about 5 mg of a bisphosphonate selected from the group consisting of alendronate, pharmaceutically acceptable salts thereof, and mixtures thereof, on an alendronic acid active weight basis” means that the amount of the bisphosphonate compound selected is calculated based on 5 mg of alendronic acid. For other bisphosphonates, the amount of bisphosphonate is calculated based on the corresponding bisphosphonic acid.
- Nonlimiting examples of bisphosphonates useful herein include the following:
- Alendronate also known as alendronate sodium or alendronate monosodium trihydrate
- 4-amino-l-hydroxybutylidene- 1,1 -bisphosphonic acid monosodium trihydrate 4-amino-l-hydroxybutylidene- 1,1 -bisphosphonic acid monosodium trihydrate.
- Kieczykowski et al. issued May 28, 1991; 5,510,517, to Treasure et al., issued April 23, 1996; 5,648,491, to Treasure et al., issued July 15, 1997, all of which are inco ⁇ orated by reference herein in their entirety.
- 1,1-dichloromethylene- 1,1 -diphosphonic acid (clodronic acid), and the disodium salt (clodronate, Procter and Gamble), are described in Belgium Patent 672,205 (1966) and J. Org. Chem 32, 4111 (1967), both of which are inco ⁇ orated by reference herein in their entirety.
- l-hydroxy-3-(l-pyrrolidinyl)-propylidene- 1,1 -bisphosphonic acid (EB-1053).
- a non-limiting class of bisphosphonates useful in the instant invention are selected from the group consisting of alendronate, cimadronate, clodronate, tiludronate, etidronate, ibandronate, neridronate, olpandronate, risedronate, piridronate, pamidronate, zolendronate, pharmaceutically acceptable salts thereof, and mixtures thereof.
- a non-limiting subclass of the above-mentioned class in the instant case is selected from the group consisting of alendronate, pharmaceutically acceptable salts thereof, and mixtures thereof.
- a non-limiting example of the subclass is alendronate monosodium trihydrate.
- the precise dosage of the bisphosphonate will vary with the dosing schedule, the particular bisphosphonate chosen, the age, size, sex and condition of the mammal or human, the nature and severity of the disorder to be treated, and other relevant medical and physical factors. Thus, a precise therapeutically effective amount cannot be specified in advance and can be readily determined by the caregiver or clinician. Appropriate amounts can be determined by routine experimentation from animal models and human clinical studies. Generally, an appropriate amount of bisphosphonate is chosen to obtain a bone reso ⁇ tion inhibiting effect, i.e. a bone reso ⁇ tion inhibiting amount of the nitrogen-containing bisphosphonate is administered. For humans, an effective oral dose of nitrogen-containing bisphosphonate is typically from about 1.5 to about 6000 ⁇ g/kg body weight and preferably about 10 to about 2000 ⁇ g/kg of body weight.
- alendronate monosodium trihydrate common human doses which are administered are generally in the range of about 2 mg/day to about 40 mg/day, preferably about 5 mg/day to about 40 mg/day.
- presently approved dosages for alendronate monosodium trihydrate are 5 mg/day for preventing osteoporosis, 10 mg/day for treating osteoporosis, and 40 mg/day for treating Paget's disease.
- the bisphosphonate can be administered at intervals other than daily, for example once-weekly dosing, twice-weekly dosing, biweekly dosing, and twice-monthly dosing.
- appropriate multiples of the bisphosphonate dosage would be administered.
- alendronate monosodium trihydrate would be administered at dosages of 35 mg/week or 70 mg/week in lieu of seven consecutive daily dosages of 5 mg or 10 mg.
- compositions herein comprise from about 1 mg to about 100 mg of bisphosphonate, preferably from about 2 mg to 70 mg, and more preferably from about 5 mg to about 70, on a bisphosphonic acid basis.
- the pharmaceutical compositions useful herein comprise about 2.5 mg, 5 mg, 10 mg, 35, mg, 40 mg, or 70 mg of the active on an alendronic acid active weight basis. See also, U.S. Patent 4,610,077, to Rosini et al., issued November 4,
- Bone Agents Further embodiments of the methods and compositions of the present invention can comprise additional bone agents useful for inhibiting bone reso ⁇ tion and providing the desired therapeutic benefits of the invention.
- additional bone agents useful for inhibiting bone reso ⁇ tion and providing the desired therapeutic benefits of the invention include those selected from the group consisting of calcitonin, estrogens,progesterone, androgens, calcium supplements, fluoride, growth hormone secretagogues, vitamin D analogues, and selective estrogen receptor modulators.
- the calcitonins useful herein can be from human or nonhuman sources, e.g. salmon calcitonin.
- Nonlimiting examples of estrogens include estradiol.
- Nonlimiting examples of selective estrogen receptor modulators include raloxifene, iodoxifene, and tamoxifene. Growth horomone secretagogues are described in U.S. Patent No. 5,536,716, to Chen et al., issued July 16, 1996, which is inco ⁇ orated by reference herein
- the farensyl diphosphate synthase inhibitors, and in further embodiments the bisphosphonate actives and any other additional actives are typically administered in admixture with suitable pharmaceutically acceptable diluents, excipients, or carriers, collectively referred to herein as "carrier materials", suitably selected with respect to the mode of administration.
- carrier materials suitable pharmaceutically acceptable diluents, excipients, or carriers, collectively referred to herein as "carrier materials”, suitably selected with respect to the mode of administration.
- suitable pharmaceutically acceptable diluents, excipients, or carriers collectively referred to herein as "carrier materials”
- suitable pharmaceutically acceptable diluents, excipients, or carriers collectively referred to herein as "carrier materials”
- the active ingredient can be combined with an oral, non-toxic, pharmaceutically acceptable inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, mannitol, sorbitol, croscarmellose sodium and the like.
- an oral, non-toxic, pharmaceutically acceptable inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, mannitol, sorbitol, croscarmellose sodium and the like.
- the oral drug components are combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like.
- suitable binders, lubricants, disintegrating agents and coloring agents can also be inco ⁇ orated.
- Suitable binders can include starch, gelatin, natural sugars such a glucose, anhydrous lactose, free-flow lactose, beta-lactose, and corn sweeteners, natural and synthetic gums, such as acacia, guar, tragacanth or sodium alginate, carboxymethyl cellulose, polyethylene glycol, waxes, and the like.
- Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like.
- An example of a tablet formulation is that described in U.S. Patent No.
- the compounds used in the present method can also be coupled with soluble polymers as targetable drug carriers.
- soluble polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxylpropyl- methacrylamide, and the like.
- Ci/mmol are obtained from ARC (St. Louis, MO).
- the crude expressed enzyme in an E. coli S100 fraction can be used.
- EXAMPLE 2 The farnesyl diphosphate synthase assay is based on the method of Rilling HS, (1985) Methods in Enzymology 110: 145-152, which is inco ⁇ orated by reference herein in its entirety. Geranyl diphosphate is used as the allylic substrate
- Bone marrow cells are then added to sub- confluent monolayers of osteoblastic MB 1.8 cells and cultured for 7 days at 37C in the presence of 5% CO2- Co-cultures are treated (1 hr at 37C) with type 1 collagenase (Wako Pure Chemical Industries, Osaka, Japan) at a concentration of 1 mg/ml in phosphate buffered saline. Suspended osteoblasts are gently aspirated, leaving an enriched mixture of prefusion osteoclasts and remaining MB 1.8 osteoblasts. These are released with EDTA (0.2 g/1 in PBS) for 20 min at 37C.
- Osteoclast co- cultures generated in 6-well plates are treated with Type XI Collagenase (Sigma) in PBS to remove all osteoblasts, followed by EDTA to remove prefusion osteoclasts. Osteoclasts (>95% purity) are then maintained in ⁇ -MEM supplemented with fetal calf serum (10% v/v) and l,25-(OH) 2 vitamin D 3 (10 nM )and M-CSF (5 ng/ml).
- osteoclasts are treated with alendronate (0-60 ⁇ M) for 2 hours before the addition of 200 ⁇ Ci of R,S-[5-
- the osteoclasts are treated with 15 ⁇ M lovastatin and alendronate (0-60 ⁇ M) for 2 hours before the
- FPP synthase catalyzes the sequential condensation of two molecules of LPP with one molecule of DMAPP to produce GPP and then FPP.
- the FPP synthase assay is run with a 15 minute preincubation and shows that alendronate inhibits FPP synthase with an IC50 of 460 nM (0.15 ⁇ g/ml). Because the inhibition of FPP synthase by alendronate is time- dependent, IC50 varies with preincubation time and assay length.
- EXAMPLE 6 Effect of alendronate on protein prenylation and the synthesis of mevalonate-derived lipids in osteoclasts: alendronate inhibition of the mevalonate pathway and of protein prenylation is demonstrated in the osteoclasts.
- a major branch point in isoprenoid metabolism occurs at FPP, which is used for sterol synthesis via squalene synthase, for prenylation of proteins via farnesyl protein transferase, for GGPP synthesis, and for the synthesis of dolichol and ubiquinone, via
- Osteoclasts are labeled with H-MVL, and the effects of alendronate on the inco ⁇ oration of the label into non-saponifiable lipids and into prenylated proteins are examined.
- the inco ⁇ oration of label from MVL into the non-saponifiable lipids is lowered by up to 80% by alendronate with an IC50 °f aroun d 15 ⁇ M. Analysis of these non-saponifiable lipids by TLC shows three major and at least five minor bands labeled. The inco ⁇ oration into all bands is lowered by alendronate without bias. Individual bands co-migrated with squalene, lanosterol, and sterols (including cholesterol, desmosterol and 7-dehydrocholesterol). A diffuse light area of labeling just under the putative lanosterol band, where farnesol, geranylgeraniol, and dolichols migrate, is also observed.
- compositions are prepared using standard mixing and formation techniques.
- Tablets containing about 1 to 100 mg of a farnesyl diphosphate synthase inhibitor are prepared using the following relative weights of ingredients.
- the resulting tablets are useful for administration in accordance with the methods of the present invention for inhibiting bone reso ⁇ tion.
- tablets are prepared that also contain 5 or 10 mg of a bisphosphonate active, on a bisphosphonic acid active basis, of a bisphosphonate selected from the group consisting of alendronate cimadronate, clodronate, tiludronate, etidronate, ibandronate, neridronate, olpandronate, risedronate, piridronate, pamidronate, zolendronate, and pharmaceutically acceptable salts thereof.
- a bisphosphonate active on a bisphosphonic acid active basis, of a bisphosphonate selected from the group consisting of alendronate cimadronate, clodronate, tiludronate, etidronate, ibandronate, neridronate, olpandronate, risedronate, piridronate, pamidronate, zolendronate, and pharmaceutically acceptable salts thereof.
- Liquid formulation liquid formulations are prepared using standard mixing techniques.
- a liquid formulation containing about 1 to about 100 mg of a farnesyl diphosphate synthase inhibitor is prepared using the following relative weights of ingredients.
- solutions are prepared also containing 5 or 10 mg of a bisphosphonate active, on a bisphosphonic acid active basis, of a bisphosphonate selected from the group consisting of alendronate cimadronate, clodronate, tiludronate, etidronate, ibandronate, neridronate, olpandronate, risedronate, piridronate, pamidronate, zolendronate, and pharmaceutically acceptable salts thereof.
- a bisphosphonate active on a bisphosphonic acid active basis, of a bisphosphonate selected from the group consisting of alendronate cimadronate, clodronate, tiludronate, etidronate, ibandronate, neridronate, olpandronate, risedronate, piridronate, pamidronate, zolendronate, and pharmaceutically acceptable salts thereof.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU33890/00A AU775239B2 (en) | 1999-03-05 | 2000-03-01 | Methods for identifying compounds useful for inhibiting farnesyl diphosphate synthase |
CA002362985A CA2362985A1 (en) | 1999-03-05 | 2000-03-01 | Methods for identifying compounds useful for inhibiting farnesyl diphosphate synthase |
JP2000602808A JP2002537819A (en) | 1999-03-05 | 2000-03-01 | Method for identifying compounds useful for inhibiting farnesyl diphosphate synthase |
EP00912106A EP1159447A4 (en) | 1999-03-05 | 2000-03-01 | Methods for identifying compounds useful for inhibiting farnesyl diphosphate synthase |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12299799P | 1999-03-05 | 1999-03-05 | |
US60/122,997 | 1999-03-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000052198A1 true WO2000052198A1 (en) | 2000-09-08 |
Family
ID=22406130
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/005338 WO2000052198A1 (en) | 1999-03-05 | 2000-03-01 | Methods for identifying compounds useful for inhibiting farnesyl diphosphate synthase |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1159447A4 (en) |
JP (1) | JP2002537819A (en) |
AU (1) | AU775239B2 (en) |
CA (1) | CA2362985A1 (en) |
WO (1) | WO2000052198A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002098354A2 (en) * | 2001-06-05 | 2002-12-12 | Merck & Co., Inc. | Compositions and methods for inhibiting bone resorption |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2682694A1 (en) * | 2007-04-12 | 2008-10-23 | The Board Of Trustees Of The University Of Illinois | Bisphosphonate compounds and methods with enhanced potency for multiple targets including fpps, ggpps, and dpps |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5103036A (en) * | 1991-05-13 | 1992-04-07 | E. R. Squibb & Sons, Inc. | Process for preparing 3-alkenylidene-1,1-bisphosphonates |
US5157027A (en) * | 1991-05-13 | 1992-10-20 | E. R. Squibb & Sons, Inc. | Bisphosphonate squalene synthetase inhibitors and method |
US5547685A (en) * | 1995-05-16 | 1996-08-20 | Eli Lilly And Company | Methods for inhibiting bone loss with vanadyl sulfate |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2783397A (en) * | 1996-05-15 | 1997-12-05 | University Of Sheffield, The | Isopentenyl pyrophosphate isomerase (ipi) and/or prenyl transferase inhibitors |
-
2000
- 2000-03-01 CA CA002362985A patent/CA2362985A1/en not_active Abandoned
- 2000-03-01 EP EP00912106A patent/EP1159447A4/en not_active Ceased
- 2000-03-01 AU AU33890/00A patent/AU775239B2/en not_active Ceased
- 2000-03-01 JP JP2000602808A patent/JP2002537819A/en not_active Withdrawn
- 2000-03-01 WO PCT/US2000/005338 patent/WO2000052198A1/en not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5103036A (en) * | 1991-05-13 | 1992-04-07 | E. R. Squibb & Sons, Inc. | Process for preparing 3-alkenylidene-1,1-bisphosphonates |
US5157027A (en) * | 1991-05-13 | 1992-10-20 | E. R. Squibb & Sons, Inc. | Bisphosphonate squalene synthetase inhibitors and method |
US5547685A (en) * | 1995-05-16 | 1996-08-20 | Eli Lilly And Company | Methods for inhibiting bone loss with vanadyl sulfate |
Non-Patent Citations (3)
Title |
---|
CHESNUT ET AL.: "Alendronate Treatment of the Postmenopausal Osteoporotic Woman: Effect of Multiple Dosages on Bone Mass and Bone Remodeling", AM. J. MED.,, vol. 99, August 1995 (1995-08-01), pages 144 - 152, XP002926793 * |
HAMDY N.: "Role of Bisphosdphonates in Metabolic Bone Diseases", TRENDS IN ENDOCRINOL. METAB.,, vol. 4, no. 1, 1993, pages 19 - 25, XP002926794 * |
See also references of EP1159447A4 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002098354A2 (en) * | 2001-06-05 | 2002-12-12 | Merck & Co., Inc. | Compositions and methods for inhibiting bone resorption |
WO2002098354A3 (en) * | 2001-06-05 | 2003-02-27 | Merck & Co Inc | Compositions and methods for inhibiting bone resorption |
Also Published As
Publication number | Publication date |
---|---|
AU775239B2 (en) | 2004-07-22 |
EP1159447A1 (en) | 2001-12-05 |
AU3389000A (en) | 2000-09-21 |
JP2002537819A (en) | 2002-11-12 |
EP1159447A4 (en) | 2004-11-03 |
CA2362985A1 (en) | 2000-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6699850B2 (en) | Compositions and methods for inhibiting bone resorption | |
Reszka et al. | Mechanism of action of bisphosphonates | |
van Beek et al. | Nitrogen-Containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potenciesin vitroandin vivo | |
Drake et al. | Bisphosphonates: mechanism of action and role in clinical practice | |
Lim et al. | Simvastatin prevents oxygen and glucose deprivation/reoxygenation‐induced death of cortical neurons by reducing the production and toxicity of 4‐hydroxy‐2E‐nonenal | |
CA2323448A1 (en) | Methods of inhibiting bone resorption | |
US20050261250A1 (en) | Compositions and methods for inhibiting bone resorption | |
US20040235797A1 (en) | Methods for identifying compounds useful for inhibiting farnesyl diphosphate synthase | |
Mallat et al. | Effect of simvastatin, an inhibitor of hydroxy-methylglutaryl coenzyme A reductase, on the growth of human Ito cells | |
US20020004218A1 (en) | Methods for identifying compounds useful for inhibiting geranylgeranyl diphosphate synthase | |
AU775239B2 (en) | Methods for identifying compounds useful for inhibiting farnesyl diphosphate synthase | |
CA2317459A1 (en) | Methods of identifying modulators of kinases responsive to stress | |
WO2000051597A1 (en) | Methods for inhibiting cathepsin k activity for the treatment of diseases related to bone loss | |
AU2001252997A1 (en) | Methods for identifying compounds useful for inhibiting geranylgeranyl diphosphate synthase | |
Monma et al. | Effects of weekly administrations of alendronate+ clodronate on young mouse tibia: localized action at the proximal growth plate | |
EP1089750A1 (en) | Compositions and methods for inhibiting bone resorption | |
US20010025028A1 (en) | Methods of inhibiting bone resorption | |
US20040180862A1 (en) | Compositions and methods for inhibiting bone resorption | |
Reszka | Bisphosphonate mechanisms of action | |
Reszka | 19 Bisphosphonate Mechanisms of Action | |
US20030078211A1 (en) | Compositions and methods for inhibiting bone resorption | |
AU2002303925A1 (en) | Compositions and methods for inhibiting bone resorption |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 33890/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000912106 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2362985 Country of ref document: CA Ref country code: CA Ref document number: 2362985 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 602808 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 2000912106 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 33890/00 Country of ref document: AU |
|
WWR | Wipo information: refused in national office |
Ref document number: 2000912106 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000912106 Country of ref document: EP |